Conv. Plasma
Nigella Sativa
Peg.. Lambda

All ivermectin studies
Meta analysis
Home COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, 24mg 30% Improvement Relative Risk Mortality, 12mg -3% Recovery time, 24mg 19% Recovery time, 12mg 6% Progression, 24mg 33% Progression, 12mg 18% Viral clearance, 24mg -33% Viral clearance, 12mg -18% Ivermectin  George et al.  LATE TREATMENT  RCT Is late treatment with ivermectin beneficial for COVID-19? RCT 112 patients in India (June 2020 - February 2021) Lower mortality (p=0.55) and faster recovery (p=0.37), not sig. George et al., Indian J. Hematology an.., May 2022 Favors ivermectin Favors control

Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial

George et al., Indian Journal of Hematology and Blood Transfusion, doi:10.1007/s12288-022-01546-w, CTRI/2020/05/025068
May 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT with 35 single dose 24mg, 38 single dose 12mg, and 39 SOC hospitalized patients with hematological illnesses in India, showing no significant differences. Results were better for 24mg vs. 12mg for all symptomatic outcomes.
Viral clearance results do not follow the randomization with less than 50% of patients tested at day 7, and no adjusted results are provided. Results were obtained for only 43.8% of ivermectin patients and 56.4% of control patients at day 7 and may not be comparable due to the large difference in the percentage of patients tested. Lower test coverage in the ivermectin group is likely related to faster recovery. Ct 40 for E or S was used for viral clearance which may also have low relevance to infectious disease.
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
This is the 35th of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 84th of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
risk of death, 30.4% lower, RR 0.70, p = 0.55, treatment 5 of 35 (14.3%), control 8 of 39 (20.5%), NNT 16, 24mg.
risk of death, 2.6% higher, RR 1.03, p = 1.00, treatment 8 of 38 (21.1%), control 8 of 39 (20.5%), 12mg.
recovery time, 18.7% lower, relative time 0.81, p = 0.37, treatment mean 4.82 (±4.35) n=35, control mean 5.93 (±5.93) n=39, 24mg.
recovery time, 6.2% lower, relative time 0.94, p = 0.78, treatment mean 5.56 (±5.42) n=38, control mean 5.93 (±5.93) n=39, 12mg.
risk of progression, 33.1% lower, RR 0.67, p = 0.41, treatment 6 of 35 (17.1%), control 10 of 39 (25.6%), NNT 12, 24mg.
risk of progression, 17.9% lower, RR 0.82, p = 0.79, treatment 8 of 38 (21.1%), control 10 of 39 (25.6%), NNT 22, 12mg.
risk of no viral clearance, 33.3% higher, RR 1.33, p = 0.50, treatment 10 of 15 (66.7%), control 11 of 22 (50.0%), subset of patients with a large difference between groups, day 7, 24mg.
risk of no viral clearance, 17.6% higher, RR 1.18, p = 0.75, treatment 10 of 17 (58.8%), control 11 of 22 (50.0%), subset of patients with a large difference between groups, day 7, 12mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
George et al., 27 May 2022, Randomized Controlled Trial, India, peer-reviewed, 15 authors, study period June 2020 - February 2021, dosage 24mg single dose, trial CTRI/2020/05/025068.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial
Biju George, Mahesh Moorthy, Uday Kulkarni, Sushil Selvarajan, Priscilla Rupali, D J Christopher, T Balamugesh, Winsley Rose, Kavitha M Lakshmi, Anup J Devasia, N A Fouzia, Anu Korula, Sharon Lionel, Aby Abraham, Vikram Mathews
Indian Journal of Hematology and Blood Transfusion, doi:10.1007/s12288-022-01546-w
Repurposed drugs may reduce morbidity and mortality in patients with hematological disorders who develop COVID-19 illness. 112 patients with predominantly hematological illnesses were randomized to receive standard of care, ivermectin 12 mg [Iv 12] or 24 mg [Iv24] for asymptomatic, mild, or moderate COVID 19 illness. Serial respiratory samples for rRT-PCR samples were sent on Day 3, 5 and 7. rRT-PCR negativity and C 2 log 10 reduction in viral loads on day 3, 5 and 7 were similar between the 3 treatment groups across all disease categories. Symptom progression occurred in 26 patients [21.6%] with no difference across 3 treatment groups. Twenty-two patients [18.3%] have expired while 98 [81.7%] survived. Survival rates were similar across treatment groups [controls-80.5%, Iv12-77.5%, Iv24-87.2% respectively]. Overall, poorer survival was seen with moderate illness compared to others [51.6% vs 92.1%; p = 0.000] and was the only significant risk factor identified on multivariate analysis. In this Phase II randomised trial, single dose of 12 or 24 mg of ivermectin did not reduce viral loads, prevent symptom progression, or reduce mortality in patients with predominantly haematological illnesses who develop mild to moderate COVID 19 illness.
Author Contributions BG, UK designed the study, interpreted the data and drafted the paper. MM designed the study, acquired of laboratory data and drafted the paper. KML analysed the data, provided critical revision of the paper and approved the final version. SS, PR, DJC, BT, WR, AJD, FNA, AK, SL, AA and VM helped in acquiring the clinical data, interpretation of data and revising the manuscript critically. All authors have approved the final submitted version of the manuscript. Declarations Conflict of interest No conflicts of interest to declare for any of the authors.
Abd-Elsalam, Noor, Badawi, Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study, J Med Virol, doi:10.1002/jmv.27122
Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID 19 may reduce the duration of illness, Int J Infect Dis
Allo, Allogeneic transplant; Auto, Autologous transplant; ANC, Absolute neutrophil count # Consisted of severe hemophilia
Bartoszko, Siemieniuk, Kum, Prophylaxis against COVID-19: living systematic review and network metaanalysis, BMJ, doi:10.1136/bmj.n949
Biernat, Kolasinska, Kwiatkowski, Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID 19, Viruses
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Chaccour, Casellas, Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, E Clin Med, doi:10.1016/j.eclinm.2020.100720
Chang, Mo, Yuan, Tao, Peng et al., Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection, Am J Respir Crit Care Med
Hueso, Pouderoux, Pere, Convalescent plasma therapy for B cell depleted patients with protracted COVID-19, Blood
Indian, Kuderer, Choueiri, Shah, Shyr et al., Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, Hematol Blood Transfus References
Jeyaraman, Agrawal, Bhargava, Convalescent plasma therapy for severe COVID 19 in patients with hematological malignancies, Transfus Apher Sci
Lee, Cazier, Angelis, Arnold, Bisht et al., COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study, Lancet
Liang, Guan, Chen, Li, Xu, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol
Liu, Yan, Xiang, Liu, Viral dynamics in mild and severe cases of COVID-19, Lancet Infect Dis
Lopez-Medina, Lopez, Hurtado, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA
Mahmud, Rahman, Alam, Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J Int Med Res, doi:10.1177/03000605211013550
Mpn, Myeloproliferative disorders; ITP, Immune thrombocytopenia; AIHA, Autoimmune hemolytic anemia
Okamus, Nemirturk, Cetinkaya, Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID 19 patients, BMC Infect Dis
Passamonti, Cattaneo, Arcaini, Clinical characteristics and risk factors associated with COVID-19 severity in patients with hematological malignancies in Italy: a retrospective multicenter cohort study, Lancet Haematol
Pinana, Martino, Garcia, Risk factors and outcomes of COVID19 in patients with hematological malignancies, Exp Hematol Oncol, doi:10.1186/s40164-020-00177-z
Prca, Pure red cell aplasia; DM, Diabetes Mellitus; HT, Hypertension; IHD, Ischaemic heart disease
Samaha, Mouawia, Fawaz, Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-Cov 2 infected subjects: a pilot clinical trial in Lebanon, Viruses
Shahbaznejad, Davoudi, Eslami, Effects of ivermectin in patients with COVID-19: a multicenter, doubleblind, randomized, controlled clinical trial, Clin Ther, doi:10.1016/j.clinthera.2021.04.007
Villegas, Poza, Talayero, IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-Cov-2 infection, Ann Hematol
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Zou, Ruan, Huang, SARS-CoV-2 Viral Load in Upper Respiratory Specimens of infected patients, NEJM
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop